MARKSANS

Marksans Pharma Limited

Source: NSE · Updated 5 Nov, 10:00 pm IST

Filed 4 Nov, 01:34 pm IST Q2 FY27 (Sep ’26)Consolidated₹ millions

Revenue

9,401.69

▲ 30.5% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

2,142.9

▲ 48.3% vs Q2 FY26

Net profit

1,435.25

▲ 44.8% vs Q2 FY26

EPS (₹)

3.12

▲ 43.8% vs Q2 FY26

Operating margin

22.8%

+270 bps vs Q2 FY26

Net margin

15.3%

+150 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+31% vs Q2 FY26 · +12% vs Q1 FY27

Profit+45% vs Q2 FY26 · −10% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	9,401.69	8,407.96	▲ 11.8%	7,204.09	▲ 30.5%
Other income	181.5	254.04	▼ 28.6%	215.72	▼ 15.9%
Total income	9,583.19	8,662	▲ 10.6%	7,419.81	▲ 29.2%
Total expenses	7,648.16	6,596.29	▲ 15.9%	6,086.47	▲ 25.7%
Operating profit (EBITDA)*	2,142.9	2,130.35	▲ 0.6%	1,444.93	▲ 48.3%
Profit before tax	1,935.03	2,065.71	▼ 6.3%	1,333.34	▲ 45.1%
Tax expense	499.78	471.64	▲ 6.0%	341.95	▲ 46.2%
Net profit	1,435.25	1,594.07	▼ 10.0%	991.39	▲ 44.8%
EPS (₹)	3.12	3.47	▼ 10.1%	2.17	▲ 43.8%
Operating margin	22.8%	25.3%	−250 bps	20.1%	+270 bps
Net margin	15.3%	19.0%	−370 bps	13.8%	+150 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ millions except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Marksans Pharma results, dividends & filings ›

Other results filed 4 Nov

TOKYOPLAST Tokyo Plast International Limited›SVLL Shree Vasu Logistics Limited›CUMMINSIND Cummins India Limited›AUSOMENT Ausom Enterprise Limited›TENNIND Tenneco Clean Air India Limited›UNIVCABLES Universal Cables Limited›TREL Transindia Real Estate Limited›ESABINDIA Esab India Limited›MAXESTATES Max Estates Limited›AUGMONT Augmont Enterprises Limited›TCC TCC Concept Limited›WANBURY Wanbury Limited›

Today's results ›

MARKSANS PHARMA Q2 FY27 ; NET PROFIT UP 45% AT ₹144 CR (YOY), DOWN 10% (QOQ)

REVENUE UP 31% AT ₹940 CR (YOY), UP 12% (QOQ)

EBITDA UP 48% AT ₹214 CR (YOY), UP 1% (QOQ)

MARGINS AT 22.8% VS 20.1% (YOY), 25.3% (QOQ)

https://resultkal.com/r/marksans-2026-11-04
Source: NSE filing · not investment advice

FAQ

When did Marksans Pharma announce Q2 FY27 results?

Marksans Pharma filed its results on NSE on 4 Nov, 01:34 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Marksans Pharma figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← MARKSANS overview